On 13 March 2026, China’s National Medical Products Administration (NMPA) granted what is widely reported as a world first: commercial approval for an invasive brain-computer interface (BCI) medical device. The approved product, the implantable hand motor function compensation system known as “NEO”, was developed by Shanghai-based Neuracle Technology in partnership with Tsinghua University, and is designed to restore partial hand movement in patients with cervical spinal cord injuries. The approval marks the moment when BCI technology transitions from clinical research into regulated, reimbursable medical practice, and signals China’s intent to compete directly in a global race that also features Elon Musk’s Neuralink, Synchron and Precision Neuroscience.
Within 48 hours of the approval, China’s National Healthcare Security Administration had assigned a medical insurance code to the product, completing the full pathway from market authorisation to clinical reimbursement in a matter of days rather than months. Investment activity in the sector reflects the broader momentum: Shanghai-based StairMed raised RMB 500 million (approximately USD 72.8 million) in a round led by Alibaba Group, whilst Chengdu-based Gestala closed RMB 150 million in angel funding for its non-invasive BCI platform. This is a sector accelerating rapidly.
A maturing and increasingly complex regulatory framework
The NEO approval was granted under China’s existing medical devices regime. Under the Regulations on the Supervision and Administration of Medical Devices (State Council Order No. 739), BCIs of this type are classified as Class III medical devices, the highest risk category, on the basis that they are powered devices that contact the body and exert a significant influence on therapeutic outcomes. Class III status carries the most demanding regulatory obligations, including NMPA approval rather than mere registration, clinical trials conducted at tertiary-grade hospitals, mandatory ethics committee review and written informed consent from participants, and a prohibition on charging trial participants for any trial-related costs.
Post-market obligations are similarly extensive. Holders of a Class III device registration certificate must implement post-market surveillance studies and risk management plans, conduct ongoing adverse event monitoring and re-evaluation, and maintain product traceability and recall systems. The registration certificate is valid for five years, with renewal applications required at least six months before expiry. These are not light obligations, and companies entering this space should plan for them from the outset rather than treat them as a downstream concern.
The dual-track system: A new dimension from May 2026
The NEO approval took place just weeks before a significant shift in China’s regulatory landscape. Since 1 May 2026, the Regulations on the Clinical Research and Clinical Translational Application of Biomedical New Technologies have been in force, creating a parallel regulatory track administered by the National Health Commission (NHC) rather than the NMPA. This track governs “biomedical new technologies”, a category broadly defined to include both invasive and non-invasive BCIs, and applies a more streamlined, institution-led model for early-stage clinical research. Under this model, internal academic and ethics committee review, followed by NHC registration within five working days, is sufficient to proceed, without the need for prior government approval.
In practice, however, the boundaries between the two tracks matter enormously, and the new framework is not the shortcut it might initially appear. Companion guidance, the Interim Guidelines on the Distinction between Biomedical New Technologies and Drugs and Medical Devices, makes clear that at the translational application stage, any technology that qualifies as a medical device within the meaning of the Medical Devices Regulations must follow the medical device regulatory pathway and cannot seek clinical translational application approval as a biomedical new technology. In short, the new framework does not create a route for invasive BCI products with a defined product form to bypass Class III device registration. Whether the biomedical new technology pathway can meaningfully serve earlier-stage BCI research, before products have crystallised into defined device forms, remains a question that will require further regulatory clarification as the framework beds in. Clients should not assume that regulatory arbitrage between the two tracks is available; the guidance is deliberately clear on this point.
A strategic industry: The policy picture
China’s commercial approval of NEO did not emerge in isolation. It reflects a deliberate and co-ordinated industrial policy push that has been building for several years. The 15th Five-Year Plan explicitly identifies BCIs as a priority future industry, calling for the development of critical enabling technologies including novel electrodes, dedicated chips, signal encoding and decoding algorithms, and Chinese-language neural datasets, as well as the application of BCI products across neurological disease treatment, motor rehabilitation and health monitoring.
Seven ministries, led by the Ministry of Industry and Information Technology and the National Development and Reform Commission, jointly published an Implementation Opinion on Promoting Innovation and Development of the BCI Industry in July 2025. That document sets concrete targets: establishing a leading technology and industrial ecosystem by 2027, and by 2030 cultivating two to three globally influential BCI companies and achieving world-class comprehensive industrial capacity. The NMPA has committed to supporting this agenda through dedicated pre-submission engagement with innovative device applicants, operating under the principle of early involvement, company-specific guidance and rolling review, which was the approach that supported the NEO approval itself.
Supporting infrastructure is advancing in parallel. An industry terminology standard for BCI medical devices (YY/T 1987–2025) entered into force in January 2026. Draft guidance on device classification and nomenclature was published for public comment in March 2026, and further regulatory instruments are anticipated. China’s first national-level BCI Research Ethics Guidelines, issued by the Ministry of Science and Technology in February 2024, had already established the ethical framework within which clinical research is expected to proceed. The direction of travel is clear: China is building a comprehensive, stable regulatory environment for BCI as a long-term strategic sector.
What this means for clients
- For medical device companies and developers, the NEO approval provides the clearest available template for navigating NMPA’s Class III registration pathway for invasive BCIs, and underscores the value of early-stage engagement under NMPA’s dedicated innovation product support mechanism. The regulatory framework is actively evolving, and the interaction between the medical devices and biomedical new technologies regimes will become clearer only as both are tested in practice. Companies should establish a process for monitoring and assessing guidance as it is published, given the pace of standard-setting in this space.
- For investors and those conducting M&A due diligence, the convergence of commercial approval, insurance coding and explicit government industrial policy support materially de-risks the market access pathway. That said, Class III registration timelines and the weight of post-market obligations remain factors that should feature prominently in target company assessments and deal structures, alongside the usual questions around IP, clinical data ownership and regulatory transfer procedures.
- For international companies seeking market access in China, China’s regulatory framework differs materially from both FDA and CE-marking pathways, notwithstanding its increasing sophistication. Existing clearances or approvals in other jurisdictions will not translate directly. Localisation of clinical evidence and regulatory strategy will remain essential, and the evolving standard-setting landscape means that what is required today may not represent the full picture by the time a market entry is complete.
- For healthcare institutions and clinical research organisations, the new biomedical new technology regime introduces additional procedural options for early-stage BCI research. The translational boundary with the medical device track must nonetheless be managed carefully to avoid regulatory uncertainty further down the line, particularly where a research programme may ultimately produce a technology with a defined product form.
China’s approval of NEO is a landmark moment, both for BCI technology globally and for China’s ambitions as a medical technology power. For clients active in this space, or considering entry, understanding the contours of China’s evolving dual-track regulatory framework is now a commercial as well as a legal priority.
For further information, please contact:
Tanya Luo, Bird & Bird
tanya.luo@twobirds.com
